Evidence map›Paper›PMID 42355430›Full record

ArticleLife (Basel, Switzerland)2026

Clinical Impact of Low-Dose Neoadjuvant Chemotherapy in Advanced Gastric Cancer or Esophagogastric Junction Cancer: A Retrospective Analysis.

Masaaki Akai, Nobuhiko Kanaya, Mikoto Shimabara, Yuta Nobunaga, Ayano Tamaki, Tsubasa Yanagihara, Toshihisa Matsumura, Kazuya Kuwada, Shoji Takagi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Masaaki AkaiDepartment of Gastroenterological Surgery, Okayama Red Cross General Hospital, 2-1-1, Aoe, Kita-ku, Okayama 700-0941, Japan.ORCID 0000-0002-0742-7272
Nobuhiko KanayaDepartment of Gastroenterological Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1, Shikata-cho, Kita-ku, Okayama 700-8558, Japan.
Mikoto ShimabaraDepartment of Gastroenterological Surgery, Okayama Red Cross General Hospital, 2-1-1, Aoe, Kita-ku, Okayama 700-0941, Japan.
Yuta NobunagaDepartment of Gastroenterological Surgery, Okayama Red Cross General Hospital, 2-1-1, Aoe, Kita-ku, Okayama 700-0941, Japan.
Ayano TamakiDepartment of Gastroenterological Surgery, Okayama Red Cross General Hospital, 2-1-1, Aoe, Kita-ku, Okayama 700-0941, Japan.
Tsubasa YanagiharaDepartment of Gastroenterological Surgery, Okayama Red Cross General Hospital, 2-1-1, Aoe, Kita-ku, Okayama 700-0941, Japan.
Toshihisa MatsumuraDepartment of Gastroenterological Surgery, Okayama Red Cross General Hospital, 2-1-1, Aoe, Kita-ku, Okayama 700-0941, Japan.
Kazuya KuwadaDepartment of Gastroenterological Surgery, Okayama Red Cross General Hospital, 2-1-1, Aoe, Kita-ku, Okayama 700-0941, Japan.
Shoji TakagiDepartment of Gastroenterological Surgery, Okayama Red Cross General Hospital, 2-1-1, Aoe, Kita-ku, Okayama 700-0941, Japan.ORCID 0009-0006-7447-2897

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aimed to evaluate the efficacy and safety of low-dose neoadjuvant chemotherapy with an oral fluoropyrimidine containing tegafur, gimeracil, and oteracil (S-1) and oxaliplatin (NAC-SOX) in improving resectability and long-term outcomes in patients with advanced gastric cancer.

methodsThis was a single-center, retrospective study analyzing patients with advanced gastric cancer or esophagogastric junction cancer who received NAC-SOX. (S-1: 80-120 mg/m

resultsA total of 34 patients underwent NAC-SOX, with a median age of 74 years. The most common surgical procedure was total gastrectomy (

conclusionsLow-dose NAC-SOX demonstrated favorable efficacy and safety, achieving high R0 resection and pathological response rates. Further prospective studies are needed to optimize treatment strategies.

Indexed as

gastric cancerlow doseneoadjuvant chemotherapyoxaliplatinS-1SOX

Identifiers

PMID42355430
PMCPMC13300859

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.